FR2811227A1 - Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs - Google Patents

Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs Download PDF

Info

Publication number
FR2811227A1
FR2811227A1 FR0008902A FR0008902A FR2811227A1 FR 2811227 A1 FR2811227 A1 FR 2811227A1 FR 0008902 A FR0008902 A FR 0008902A FR 0008902 A FR0008902 A FR 0008902A FR 2811227 A1 FR2811227 A1 FR 2811227A1
Authority
FR
France
Prior art keywords
sep
heparin
particulate
particulate vectors
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR0008902A
Other languages
English (en)
French (fr)
Inventor
Philippe Maincent
Nathalie Ubrich
Claude Vigneron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0008902A priority Critical patent/FR2811227A1/fr
Priority to CA2415414A priority patent/CA2415414C/fr
Priority to PT01984141T priority patent/PT1313453E/pt
Priority to JP2002508415A priority patent/JP5175017B2/ja
Priority to MXPA03000193A priority patent/MXPA03000193A/es
Priority to CN01812448A priority patent/CN1440277A/zh
Priority to RU2003103596/15A priority patent/RU2003103596A/ru
Priority to US10/332,351 priority patent/US8052998B2/en
Priority to BRPI0112080A priority patent/BRPI0112080B1/pt
Priority to DK01984141T priority patent/DK1313453T3/da
Priority to KR10-2003-7000198A priority patent/KR20030038655A/ko
Priority to DE60134147T priority patent/DE60134147D1/de
Priority to EP01984141A priority patent/EP1313453B1/fr
Priority to AU2002218745A priority patent/AU2002218745A1/en
Priority to ES01984141T priority patent/ES2305121T3/es
Priority to PCT/FR2001/002159 priority patent/WO2002003960A1/fr
Priority to AT01984141T priority patent/ATE395906T1/de
Publication of FR2811227A1 publication Critical patent/FR2811227A1/fr
Priority to US12/779,556 priority patent/US8257744B2/en
Priority to US13/355,763 priority patent/US8361509B2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FR0008902A 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs Pending FR2811227A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR0008902A FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
DK01984141T DK1313453T3 (da) 2000-07-07 2001-07-05 Partikelformige bærere til at forbedre oral absorbtion af aktive stoffer
KR10-2003-7000198A KR20030038655A (ko) 2000-07-07 2001-07-05 유효성분의 경구 흡수를 개선하기 위한 미립자 벡터
JP2002508415A JP5175017B2 (ja) 2000-07-07 2001-07-05 有効成分の経口吸収を改善するための粒子状担体
MXPA03000193A MXPA03000193A (es) 2000-07-07 2001-07-05 Vectores en particulas para mejorar la absorcion oral de los principios activos.
CN01812448A CN1440277A (zh) 2000-07-07 2001-07-05 改进活性成分口服吸收的微粒载体
RU2003103596/15A RU2003103596A (ru) 2000-07-07 2001-07-05 Носитель в виде частиц, предназначенный для улучшения перорального всасывания активных начал
US10/332,351 US8052998B2 (en) 2000-07-07 2001-07-05 Particulate vectors for improving oral absorption of active principles
BRPI0112080A BRPI0112080B1 (pt) 2000-07-07 2001-07-05 vetores particulados para aperfeiçoamento da absorção oral de principios ativos
CA2415414A CA2415414C (fr) 2000-07-07 2001-07-05 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
PT01984141T PT1313453E (pt) 2000-07-07 2001-07-05 Vectores particulados destinados a melhorar a absorção oral de princípios activos
DE60134147T DE60134147D1 (de) 2000-07-07 2001-07-05 Träger in partikelform zur verbesserung der oral- absorption von wikstoffen
EP01984141A EP1313453B1 (fr) 2000-07-07 2001-07-05 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
AU2002218745A AU2002218745A1 (en) 2000-07-07 2001-07-05 Particulate vectors for improving oral absorption of active principles
ES01984141T ES2305121T3 (es) 2000-07-07 2001-07-05 Vectores en forma de particulas destinados a mejorar la absorcion oral de principios activos.
PCT/FR2001/002159 WO2002003960A1 (fr) 2000-07-07 2001-07-05 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
AT01984141T ATE395906T1 (de) 2000-07-07 2001-07-05 Träger in partikelform zur verbesserung der oral- absorption von wikstoffen
US12/779,556 US8257744B2 (en) 2000-07-07 2010-05-13 Pharmaceutical forms for the release of active compounds
US13/355,763 US8361509B2 (en) 2000-07-07 2012-01-23 Pharmaceutical dosage forms for the release of active compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0008902A FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs

Publications (1)

Publication Number Publication Date
FR2811227A1 true FR2811227A1 (fr) 2002-01-11

Family

ID=8852251

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0008902A Pending FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs

Country Status (17)

Country Link
US (1) US8052998B2 (https=)
EP (1) EP1313453B1 (https=)
JP (1) JP5175017B2 (https=)
KR (1) KR20030038655A (https=)
CN (1) CN1440277A (https=)
AT (1) ATE395906T1 (https=)
AU (1) AU2002218745A1 (https=)
BR (1) BRPI0112080B1 (https=)
CA (1) CA2415414C (https=)
DE (1) DE60134147D1 (https=)
DK (1) DK1313453T3 (https=)
ES (1) ES2305121T3 (https=)
FR (1) FR2811227A1 (https=)
MX (1) MXPA03000193A (https=)
PT (1) PT1313453E (https=)
RU (1) RU2003103596A (https=)
WO (1) WO2002003960A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060253A1 (en) * 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
DE602004003577T2 (de) * 2003-04-17 2007-09-20 Jallal Messadek Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
WO2006088647A1 (en) * 2005-02-17 2006-08-24 Medivas, Llc Polymer particle delivery compositions and methods of use
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
BRPI0610249A2 (pt) * 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina
CA2623239C (en) 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2213282A1 (en) * 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
DE102012019029A1 (de) 2012-09-27 2014-03-27 Alf Lamprecht Arzneiformulierungen zur oralen Gabe von therapeutischen Substanzen und Verfahren zur Herstellung
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011844A1 (en) * 1991-01-03 1992-07-23 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
WO1994014420A1 (en) * 1992-12-21 1994-07-07 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
WO1996028143A1 (de) * 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
FR2769853A1 (fr) * 1997-10-21 1999-04-23 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
HK1040910B (en) * 1998-11-12 2009-06-26 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and metformin
AU3471400A (en) * 1999-01-19 2000-08-07 Children's Hospital Of Philadelphia, The Compositions and methods for controlled delivery of virus vectors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011844A1 (en) * 1991-01-03 1992-07-23 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
WO1994014420A1 (en) * 1992-12-21 1994-07-07 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
WO1996028143A1 (de) * 1995-03-10 1996-09-19 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
FR2769853A1 (fr) * 1997-10-21 1999-04-23 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises

Also Published As

Publication number Publication date
CA2415414A1 (fr) 2002-01-17
DK1313453T3 (da) 2008-09-22
RU2003103596A (ru) 2004-08-20
ATE395906T1 (de) 2008-06-15
CA2415414C (fr) 2011-08-23
WO2002003960A1 (fr) 2002-01-17
BR0112080A (pt) 2003-05-06
BRPI0112080B1 (pt) 2017-01-24
PT1313453E (pt) 2008-07-16
EP1313453A1 (fr) 2003-05-28
MXPA03000193A (es) 2004-09-13
ES2305121T3 (es) 2008-11-01
EP1313453B1 (fr) 2008-05-21
JP2004502720A (ja) 2004-01-29
AU2002218745A1 (en) 2002-01-21
JP5175017B2 (ja) 2013-04-03
US20050013866A1 (en) 2005-01-20
CN1440277A (zh) 2003-09-03
US8052998B2 (en) 2011-11-08
KR20030038655A (ko) 2003-05-16
DE60134147D1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
EP1313453B1 (fr) Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8361509B2 (en) Pharmaceutical dosage forms for the release of active compounds
KR100638041B1 (ko) 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US8974819B2 (en) Sustained-release chitosan capsules comprising chitosan and phytic acid
CN107661490B (zh) 包含格拉默或其药用盐的储药系统
EP2679227B1 (en) Nanoparticle containing prostaglandin i2 derivative
US20250009664A1 (en) Dosage form for intra-articular injection comprising colchicine for use in the treatment of crystal-and non-crystal associated acute inflammatory arthritis
US20100143484A1 (en) Oral submicron particle delivery system for proteins and process for its production
JP2022103337A (ja) カルベジロール分散系の非経口徐放送達
Picu et al. Nanobased scientific and technological solutions for the management of diabetes mellitus
WO2001049264A2 (fr) Compositions pharmaceutiques destinees a une administration par voie orale
WO2007036946A1 (en) Compositions for enhanced absorption of biologically active agents
EP2219611B1 (en) Pharmaceutical forms for the release of active compounds
CN116585304B (zh) 一种急性肝损伤保护药物及其制备方法
WO2013010238A1 (pt) Composições farmacêuticas microparticuladas contendo antiparasitarios para terapia subcutânea prolongada, uso das ditas composições farmacêuticas para a produção de um medicamento e método de tratamento de parasitoses.
WO2025012469A1 (en) Polymeric microparticles loaded with nanoparticles for the delivery of nucleic acids
HK1057475A (en) Particulate vectors for improving oral absorption of active principles
Hill Pharmacokinetic analysis and formulation development of therapeutic proteins
WO2017134655A1 (en) Improved oral absorption of octreotide and salts thereof
TW201125578A (en) A sustained preparation of Factor IX